SuperworthCentene EPS CNC
Diluted earnings per share by quarter and over the last twelve months, from 2009.
- Last 12 months, to Jun 30, 2026
- −$10.44
- Latest quarter, Q2 FY26
- $2.19
- Fiscal year 2025
- −$13.62
- −318% on the year before
Centene's earnings per share was −$10.44 over the twelve months to Jun 30, 2026, down 358% on a year earlier.
In its latest quarter, Q2 FY26, it was $2.19.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$13.62 | −318% |
| FY2024 | $6.24 | +27% |
| FY2023 | $4.91 | +141% |
| FY2022 | $2.04 | −10% |
| FY2021 | $2.27 | −26% |
| FY2020 | $3.08 | −2% |
| FY2019 | $3.14 | +35% |
| FY2018 | $2.33 | −1% |
| FY2017 | $2.35 | +48% |
| FY2016 | $1.58 | +10% |
| FY2015 | $1.45 | +28% |
| FY2014 | $1.13 | +54% |
| FY2013 | $0.73 | +29100% |
| FY2012 | $0.00 | −100% |
| FY2011 | $0.53 | +13% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $2.19 | n/a | −$10.44 | |
| Q1 FY26 | $3.11 | +18% | −$13.14 | |
| Q4 FY25 | −$2.24 | −500% | −$13.62 | |
| Q3 FY25 | −$13.50 | −1093% | −$10.82 | |
| Q2 FY25 | −$0.51 | −124% | $4.04 | |
| Q1 FY25 | $2.63 | +22% | $6.71 | |
| Q4 FY24 | $0.56 | +600% | $6.24 | |
| Q3 FY24 | $1.36 | +56% | $5.76 | |
| Q2 FY24 | $2.16 | +13% | $5.27 | |
| Q1 FY24 | $2.16 | +6% | $5.03 | |
| Q4 FY23 | $0.08 | n/a | $4.91 | |
| Q3 FY23 | $0.87 | −31% | $4.45 |
Against its peers
Companies in Medical - Healthcare Plans nearest Centene's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CNCCentene | −$10.44 | −358% a year |
| HUMHumana | $10.57 | −19% a year |
| CICigna | $24.17 | +32% a year |
| ELVElevance Health | $22.50 | −4% a year |
| CVSCVS Health | $3.79 | +6% a year |
| OSCROscar Health | $1.39 | |
| Peer median | $10.57 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Centene
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.